ARGONAUT-III and -V: susceptibility of carbapenem-resistant Klebsiella pneumoniae and multidrug-resistant Pseudomonas aeruginosa to the bicyclic boronate β-lactamase inhibitor taniborbactam combined with cefepime is a research paper published in Antimicrobial Agents and Chemotherapy (2024). On theSindex it has a DataRank of 0. It has been cited 14 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
HHS | NIH | National Institute of Allergy and Infectious Diseases
Grant: R21AI114508
U.S. Department of Veterans Affairs
Grant: 1I01BX001974
U.S. Department of Veterans Affairs
Grant: 1I01BX002872
HHS | NIH | National Institute of Allergy and Infectious Diseases
Grant: UM1AI104681
National Institutes of Health
Grant: 5R21AI114508-02
Molecular Epidemiology of Carbapenem-Resistant Klebsiella pneumoniae
National Institutes of Health
Grant: 5I01BX001974-11
The Continuing Challenge of Carbapenemases in K. pneumoniae: KPC-2 & NDM-1
National Institutes of Health
Grant: 5I01BX002872-03
Targeting Burkholderial beta-lactamases: Structure, function, and regulation
National Institutes of Health
Grant: 5UM1AI104681-03
Antibacterial Resistance Leadership Group (ARLG)
Fields of Study
Sustainable Development Goals